Clinical Trials
16 trialsNCT06171685 2026-06-05
MMRC Horizon One: RRMM (MMRC-099)
Multiple Myeloma Research Consortium
Phase 2 Active not recruiting
NCT07085728 2026-05-15
Testing the Investigational Agent Combination of Daratumumab, Bortezomib, and Dexamethasone Compared to the Usual Treatment of Cyclophosphamide, Bortezomib, and Dexamethasone in Newly Diagnosed Multiple Myeloma Patients With Kidney Failure
Eastern Cooperative Oncology Group
Phase 2 Active not recruiting
NCT04166565 2026-04-20
EMN19
European Myeloma Network B.V.
Phase 2 Active not recruiting
NCT04667663 2026-04-13
CPD-DARA
Cancer Trials Ireland
Phase 1 Active not recruiting
NCT05208086 2026-04-13
RHUMM
Intergroupe Francophone du Myelome
Active not recruiting
NCT06062537 2026-04-13
TEC-CARE
Intergroupe Francophone du Myelome
Active not recruiting
NCT05257083 2026-03-17
CARTITUDE-6
European Myeloma Network B.V.
Phase 3 Active not recruiting
NCT03710603 2026-02-10
Perseus
European Myeloma Network B.V.
Phase 3 Active not recruiting
NCT05028348 2025-12-04
A Study of Combination of Selinexor, Pomalidomide, and Dexamethasone (SPd) Versus Elotuzumab, Pomalidomide, and Dexamethasone (EloPd) in Subject With Previously Treated Multiple Myeloma
European Myeloma Network B.V.
Phase 3 Active not recruiting
NCT04071457 2025-09-15
DRAMMATIC
SWOG Cancer Research Network
Phase 3 Active not recruiting
NCT01863550 2025-09-08
Bortezomib or Carfilzomib With Lenalidomide and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma
Eastern Cooperative Oncology Group
Phase 3 Active not recruiting
NCT03896737 2025-08-11
Daratumumab-bortezomib-dexamethasone (Dara-VCd) vs Bortezomib-Thalidomide-Dexamethasone (VTd), Then Maintenance With Ixazomib (IXA) or IXA-Dara
European Myeloma Network B.V.
Phase 2 Active not recruiting
NCT05123131 2025-07-08
Isa-RVD
Cancer Trials Ireland
Phase 2 Active not recruiting
NCT04483739 2025-02-26
IsKia
European Myeloma Network B.V.
Phase 3 Active not recruiting
NCT04564703 2025-02-25
Iberdomide (Cc220) Maintenance After Asct in Newly Diagnosed MM Patients
European Myeloma Network B.V.
Phase 2 Active not recruiting
NCT04934475 2024-11-07
MIDAS
Intergroupe Francophone du Myelome
Phase 3 Active not recruiting